H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 18.08 CNY -2.01% Market Closed
Market Cap: 10.9B CNY
Have any thoughts about
Hualan Biological Bacterin Inc?
Write Note

Hualan Biological Bacterin Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hualan Biological Bacterin Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Pre-Tax Income
ÂĄ1B
CAGR 3-Years
-2%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Pre-Tax Income
-ÂĄ6.2B
CAGR 3-Years
18%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Pre-Tax Income
-ÂĄ1.3B
CAGR 3-Years
-1%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Pre-Tax Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Pre-Tax Income
ÂĄ4.2B
CAGR 3-Years
-27%
CAGR 5-Years
11%
CAGR 10-Years
39%
Imeik Technology Development Co Ltd
SZSE:300896
Pre-Tax Income
ÂĄ2.2B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
10.8B CNY
Industry
Biotechnology

In the bustling landscape of biotechnology, Hualan Biological Bacterin Inc. emerges as a formidable player. This Chinese company, rooted in the province of Henan, has carved its niche in the development and manufacture of human vaccines. Hualan's journey began with a focused vision on advancing public health through immunization. Today, it stands among the largest producers of human vaccines in China, adeptly navigating the stringent regulatory environments that govern this critical sector. The company's innovative approach in vaccine research is bolstered by state-of-the-art facilities and an unwavering commitment to quality, enabling it to produce safe, effective, and affordable vaccines. Over the years, Hualan has expanded its portfolio to include vaccines for influenza, rabies, and measles, to name a few, each product carefully developed to meet domestic and international health needs. Hualan Biological Bacterin Inc. generates its revenues substantially through the sale of these vaccines. The company's business model leans heavily on its strong distribution network, which ensures that its products effectively reach healthcare providers and institutions across China. Regulatory approvals for new vaccines further pave the way for market expansion and potential export opportunities, contributing to revenue growth. Furthermore, the company strategically invests in research and development, consistently working on new immunological breakthroughs, thus securing its standing and paving the way for future revenue streams. Through this meticulous combination of development, regulatory savvy, and strategic distribution, Hualan not only sustains its financial health but continues to play a vital role in advancing global public health.

Intrinsic Value
30.95 CNY
Undervaluation 42%
Intrinsic Value
Price
H

See Also

What is Hualan Biological Bacterin Inc's Pre-Tax Income?
Pre-Tax Income
1B CNY

Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Pre-Tax Income amounts to 1B CNY.

What is Hualan Biological Bacterin Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
27%

Over the last year, the Pre-Tax Income growth was 71%. The average annual Pre-Tax Income growth rates for Hualan Biological Bacterin Inc have been -2% over the past three years , 27% over the past five years .

Back to Top